Activation of NK cells by ADCC antibodies and HIV disease progression.
about
Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and PersistenceConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingAntibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaquesInfluence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells.The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individualsIdentification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.Human immunodeficiency virus vaccinesHIV-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) -Mediating Antibodies Decline while NK Cell Function Increases during Antiretroviral Therapy (ART).HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humansA novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assaysEnv-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular CytotoxicityThe role of Fc receptors in HIV prevention and therapy.Antibody-dependent CD56+ T cell responses are functionally impaired in long-term HIV-1 infection.Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women.Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes.Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat ProteinInteraction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality.Role of Fc-mediated antibody function in protective immunity against HIV-1.Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.Use of broadly neutralizing antibodies for HIV-1 prevention.Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.HIV-specific antibody-dependent phagocytosis matures during HIV infection.Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees.Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.HIV antibodies for treatment of HIV infection.Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial.Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.Natural Killer cells in HIV-1 infection and therapy.Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease.Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy.
P2860
Q26767362-6722C4B8-8060-486A-9A16-10AA452B2785Q26782237-8AFF577E-2BD9-4F2A-A846-ABC49B8B4498Q27675486-F03BD029-E065-4C25-990D-9739CD2C84F6Q30427950-01EC94B6-9B26-45C6-A68D-02D94C50823DQ34305570-0C099088-6ED0-49A6-B93B-E7E7D0EFE2F3Q34992575-A8C4A1D4-96C3-4089-9110-42C94A2722C4Q35600028-F1DD2AA8-F79C-48BE-88DA-24ADB8405537Q35674731-1C474C18-EB61-42DB-ACE5-7E1F97052A8AQ35876207-5E607370-ADA1-4F8C-B496-55572992FCC2Q36252656-26686C7D-1D6C-49F6-9D50-48BEEA29DB51Q36363866-1A56F478-4FA4-4BBC-A13B-83A163E55CB2Q36434229-4C347D43-099D-49C4-9B4B-3AD01EF0358BQ37113972-29665CDD-2019-4850-8CC2-A62F6F977A50Q37396363-184E871B-F297-448A-B0EB-7A4866652F2AQ37409262-E8EB6B84-F828-48B1-981D-6049638FD0D3Q37460091-AADAB593-AB26-4320-A994-3DA5D79762E0Q37505357-7028D50F-DF16-4BA0-A89C-BE0AEB0A482DQ37523341-B76C2632-5696-4E60-8C8A-029A0F9DFF46Q37592654-39524606-AEC6-4265-9172-B6DB1AFAE777Q37644079-9D37E22E-58D8-4F74-9196-E50A835DF0E5Q38061191-4D430F29-E803-4A84-9295-03B0DE85BE09Q38213061-F35D8F25-3417-4167-8788-5F1180964B4CQ38527822-AF5CFF5D-F18B-4C82-BAB6-35D2EE625ACAQ38658529-C0EAF836-CF21-4965-9E2E-848B4EC91500Q38682077-89EFE581-9C4D-42FF-A70A-EC67D467FA31Q38727815-700ABB50-3C6D-4373-A9DA-A8D23B2B8789Q38764543-B40A660C-3168-4D38-8B49-04C8D1C13940Q38812544-0D78FAE5-8C0E-4066-A179-1ACC46DC58A0Q38873975-96F1F0DD-67B6-4AA0-A3B7-E759FFF7E314Q38945522-14B7FF25-DFA0-40DE-B1D3-6C4E0183ABC7Q38998925-DDAD45C3-9592-443B-A36F-D7817E9D0535Q39108716-FE208931-30E7-4340-9697-369DD67222C4Q39189458-08485C69-7A2F-464A-8585-1EC9E78A08EFQ40052007-46225A21-CC5F-4E90-9DDA-1DFFCC6012E8Q40172220-68F159E3-D2B9-49DD-A77E-17B4476BC18DQ40366464-5BC318C6-EBFD-4744-8422-6E3BD19D6815Q41924059-950B366F-8121-46AA-8C28-0D3E10F97017Q41934634-C24D22DC-945A-427B-AFCD-9C82221EEE3EQ42130441-8C4BAEBB-C2C8-49F4-AF20-591C73796199Q42199049-3E54C451-93D2-460A-94DC-E015F4395682
P2860
Activation of NK cells by ADCC antibodies and HIV disease progression.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Activation of NK cells by ADCC antibodies and HIV disease progression.
@ast
Activation of NK cells by ADCC antibodies and HIV disease progression.
@en
type
label
Activation of NK cells by ADCC antibodies and HIV disease progression.
@ast
Activation of NK cells by ADCC antibodies and HIV disease progression.
@en
prefLabel
Activation of NK cells by ADCC antibodies and HIV disease progression.
@ast
Activation of NK cells by ADCC antibodies and HIV disease progression.
@en
P2093
P2860
P50
P1476
Activation of NK cells by ADCC antibodies and HIV disease progression.
@en
P2093
Gamze Isitman
Julie Silvers
Marjon Navis
P2860
P304
P356
10.1097/QAI.0B013E31822C62B9
P407
P577
2011-10-01T00:00:00Z